Socio-demographic Profile and Economic Burden of Treatment of Transfusion Dependent Thalassemia
Overview
Authors
Affiliations
Objective: To compile the socio-demographic profile and estimate the economic burden of transfusion dependent thalassemia.
Methods: This cross-sectional descriptive study was conducted at a tertiary care hospital in north India. Transfusion dependent thalassemia patients on regular blood transfusion for at least a year were selected. Thalassemia diagnosis was based on HPLC and/or mutation analysis results. Clinical and laboratory parameters were collected from electronic health records. Information regarding socio-economic profile and costs incurred, including indirect costs were collected by interviewing patients' guardians. The data was analyzed as a whole cohort and also in subgroups based on age.
Results: The data of 261 patients with a median age of 127 mo was collected. The median age at diagnosis was 9.8 mo. The total treatment expenses of a patient per year ranged from US$ 629 (INR 41,514) to US$ 2300 (INR 151,800), in the different age groups, at an average of US$ 1135 (INR 74,948). More than half (53%) of this was spent on medications. On an average, 38.8% of the family income was spent on the treatment of a thalassemia patient annually. Only 19 of 262 cases had an average pre-BT Hb ≥ 9 g/dl and serum ferritin ≤1500 ng/dl.
Conclusions: The treatment for transfusion dependent thalassemia is costly and mostly borne by the families in India. This study provides a realistic magnitude of this burden and will be useful in planning a thalassemia management program at the state or national level.
Systematic literature review of the indirect costs and humanistic burden of β-thalassemia.
Aydinok Y, Purushotham S, Yucel A, Glassberg M, Deshpande S, Potrata B Ther Adv Hematol. 2024; 15:20406207241270872.
PMID: 39297078 PMC: 11409307. DOI: 10.1177/20406207241270872.
Global Globin Network and adopting genomic variant database requirements for thalassemia.
Halim-Fikri H, Zulkipli N, Alauddin H, Bento C, Lederer C, Kountouris P Database (Oxford). 2024; 2024.
PMID: 39231257 PMC: 11373567. DOI: 10.1093/database/baae080.
Anne P, Gupta A, Misra S, Sharma S, Garg M, Bajpayee A Indian J Hematol Blood Transfus. 2023; 39(2):317-324.
PMID: 37006984 PMC: 10064373. DOI: 10.1007/s12288-022-01564-8.
Safety and Efficacy of Thalidomide and Hydroxyurea Combination in Beta Thalassemia Patients.
Garg A, Patel K, Shah K, Trivedi D, Raj A, Yadav R Indian J Hematol Blood Transfus. 2023; 39(1):85-89.
PMID: 36699430 PMC: 9868204. DOI: 10.1007/s12288-022-01536-y.
Alshamsi S, Hamidi S, Narci H BMC Health Serv Res. 2022; 22(1):304.
PMID: 35248046 PMC: 8897869. DOI: 10.1186/s12913-022-07663-6.